


# Patient involvement in the development process & early access

## An industry perspective


Lode Dewulf, 14 Dec 2015, London

EMA-EBE Regulatory Policy Summit 2015

# The definition of innovation is changing *From linear with the patient at the end*




### The definition of innovation is changing To circular with the patient engaged all the time



Patient Engagement throughout the development 3 Current Key Challenges for Industry

**1**.From the population average to the individual patient

### The ghost of Karl Friedrich Gauss...



Patient Engagement throughout the development 3 Current Key Challenges for Industry

**1**.From the population average to the individual patient

**2**. Medicine Development is global and Patient Engagement is local

#### We need an ICH on Patient Engagement

Review Article

#### Partnering With Patients in the Development and Lifecycle of Medicines: A Call for Action

Therapeutic Innovation & Regulatory Science I-II © The Author(s) 2015 Reprints and permission: sagepub.com/journals/Permissions.nav D OI: 10.1177/2168479015580384 tirs.sagepub.com

Anton Hoos, MD<sup>1</sup>, James Anderson, MA, MBA<sup>2</sup>, Marc Boutin, JD<sup>3</sup>, Lode Dewulf, MD, Dip Pharm Med, FFPM<sup>4</sup>, Jan Geissler, Dipl-Kfm<sup>5</sup>, Graeme Johnston, LLB, IPFA<sup>6</sup>, Angelika Joos, MPharm<sup>7</sup>, Marilyn Metcalf, PhD<sup>8</sup>, Jeanne Regnante, MS<sup>9</sup>, Ifeanyi Sargeant, DPhil<sup>10</sup>, Roslyn F. Schneider, MD, MSc<sup>11</sup>, Veronica Todaro, MPH<sup>12</sup>, and Gervais Tougas, MD, CM<sup>13</sup>

#### Abstract

The purpose of medicines is to improve patients' lives. Stakeholders involved in the development and lifecycle management of medicines agree that more effective patient involvement is needed to ensure that patient needs and priorities are identified and met. Despite the increasing number and scope of patient involvement initiatives, there is no accepted master framework for systematic patient involvement in industry-led medicines research and development, regulatory review, or market access decisions. Patient engagement is very productive in some indications, but inconsistent and fragmentary on a broader level. This often results in inefficient drug development, increasing evidence requirements, lack of patient-centered outcomes that address unmet medical needs and facilitate adherence, and consequently, lack of required therapeutic options and high costs to society and involved parties. Improved patient involvement can drive the development of innovative medicines that deliver more relevant and impactful patient. outcomes and make medicine development faster, more efficient, and more productive. It can lead to better prioritization of early research; improved resource allocation; improved trial protocol designs that better reflect patient needs; and, by addressing potential barriers to patient participation, enhanced recruitment and retention. It may also improve trial conduct and lead to more focused, economically viable clinical trials. At launch and beyond, systematic patient involvement can also improve the ongoing benefit-risk assessment, ensure that public funds prioritize medicines of value to patients, and further the development of the medicine. Progress toward a universal framework for patient involvement requires a joint, precompetitive, and international approach by all stakeholders, working in true partnership to consolidate outputs from existing initiatives, identify gaps, and develop a comprehensive framework. It is essential that all stakeholders participate to drive adoption and implementation of the framework and to ensure that patients and their needs are embedded at the heart of medicines development and lifecycle management.

#### Keywords

patient involvement, medicines development

- <sup>1</sup> M4P (Medicines 4 Patients) Consulting London, UK
- <sup>2</sup> GaxoSmithKline, Brendord, Middlesex, UK
- <sup>3</sup> National Health Council, Washington, DC, USA
- <sup>4</sup> UCB Biopharma, Brussels, Belgium



#### We need to map and synergize Patient Engagement I


We need to map and share Patient Engagement P

G

#### **PFMD launched in October 2015**

#### www.pfmd.org

#### Patient Focused Medicine Development in a nutshell




made

9

## **PFMD launched in October 2015**

www.pfmd.org

**Our Path Forward** 



Conduct a landscape assessment of initiatives that involve the patient.

Develop a platform allowing for cross- pollination.

Synergize and globalize good practices into an integrated patient involvement framework.

urt

Patient Engagement throughout the development 3 Current Key Challenges for Industry

**1**.From the population average to the individual patient

**2**. Medicine Development is global and Patient Engagement is local

**3**. Engagement requires trust and Industry still faces distrust

# Patient Engagement throughout the development *How we can build trust*

#### Ρ

- The science of Patient Input
- Early access is not a short cut

#### • Patient Engagement is largely pre-competitive

• Companies already collaborate; other stakeholders need to join

### Thank you

A history of medicine...

Accident Based Medicine A

- Belief Based Medicine B
- Cash Based Medicine C
- Data Based Medicine D
- EVIDENCE Based Medicine E
- EXPERIENCE Based Medicine E

From EBM to EMB 2.0

**Evidence** 

**Experience** 

# The line between research and practice is fading.

.E T |

#### What is the definition and scope of RWE?

<u>ABPI definition</u>: Normal clinical practice

<u>Proposed definition</u>: clinical practice *plus* Normal Life Living with a disease

